Enterprising achievements accordion
Our partnership with Moderna is redefining healthcare innovation worldwide, with the launch of Moderna’s state-of-the-art vaccine manufacturing facility on our Clayton campus.
As the first facility of its kind in the Southern Hemisphere, and the first on a university campus globally, it underscores our leadership in translational research and innovation.
In April, we hosted the World Health Summit Regional Meeting in Melbourne, marking the first time this prestigious event was held in Australia.
This year’s standout achievement was Seaport Therapeutics, which secured a total capital raise of US$325 million by licensing the Monash Glyph™ technology platform. Developed by Professor Chris Porter and his MIPS team, this proprietary platform advances best-in-class drugs for central nervous system-related conditions, including neuropsychiatric diseases, anxiety, mood disorders and epilepsy.
University-led biotechs Myostellar and GILZRx, each securing an additional $500,000 from the Brandon BioCatalyst’s CUREator incubator this year, are developing therapies for skeletal muscle regeneration to treat previously untreatable muscle disorders such as Duchenne Muscular Dystrophy.
Phrenix Therapeutics, recognised at the 2024 Monash University Vice-Chancellor’s Excellence Awards, is pioneering treatments for cognitive impairments tied to schizophrenia and other psychiatric conditions.
ElectraLith is transforming lithium production with a novel membrane technology that enables direct extraction and refining from salt lakes, mine tailings and other solutions without additional water or chemicals. The company is finalising an oversubscribed $27.5 million Series A funding round.